Literature DB >> 6732864

Teratogen metabolism: activation of thalidomide and thalidomide analogues to products that inhibit the attachment of cells to concanavalin A coated plastic surfaces.

A G Braun, S L Weinreb.   

Abstract

Thalidomide metabolites inhibited the attachment of tumor cells to concanavalin A coated polyethylene surfaces. Thalidomide, itself, was non-inhibitory. Thalidomide activation to inhibitory products required hepatic microsomes, an NADPH-generating system, and molecular oxygen. Production of inhibitory metabolites was unaffected by either epoxide hydrolase or 1,2-epoxy-3,3,3-trichloropropane (TCPO), an inhibitor of epoxide hydrolase endogenous to hepatic S9 fraction. Therefore, the attachment inhibitor was probably not an arene oxide. Inhibition was not accompanied by cytotoxicity, as judged by trypan blue exclusion. Although uninduced hepatic microsomes from mice, rats and dogs had similar abilities to activate thalidomide, microsomes from Aroclor 1254 induced rats were relatively inactive in the system. Inhibitory metabolites were generated from the thalidomide analogues EM8 , EM12 , EM16 , EM87 , EM136 , EM255 , E350 , phthalimide, phthalimido-phthalimide, indan, 1- indanone and 1,3- indandione . Glutarimide , glutamic acid and phthalic acid did not activate to inhibitory products.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732864     DOI: 10.1016/0006-2952(84)90415-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  In vitro screening assay for teratogens using growth inhibition of human embryonic cells.

Authors:  R M Pratt; W D Willis
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

Review 2.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

3.  Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages.

Authors:  A Tadesse; E J Shannon
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

4.  Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood.

Authors:  R Neubert; A C Nogueira; D Neubert
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

5.  Teratologic studies on the Himalayan rabbit: new aspects of thalidomide-induced teratogenesis.

Authors:  H Sterz; H Nothdurft; P Lexa; H Ockenfels
Journal:  Arch Toxicol       Date:  1987-07       Impact factor: 5.153

Review 6.  The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information.

Authors:  P M Wood; S J Proctor
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.